The clinical story began weeks before the arrest. The patient had previously undergone a transcatheter aortic valve replacement for severe aortic stenosis, a narrowing of the heart’s outflow valve that forces the heart to pump against crushing resistance. When that bioprosthetic valve began failing again, he developed the classic signs of congestive heart failure: worsening shortness of breath, an inability to lie flat, and chest pain. His medical history compounded the danger. He had coronary artery disease treated with a drug-eluting stent in the left anterior descending artery, and he was on long-term hemodialysis for end-stage renal disease. An echocardiogram revealed a mean gradient of 43 mmHg across the valve with a peak velocity of 3.98 meters per second, both indicating severe obstruction, while his left ventricular ejection fraction had collapsed from 35 to 40 percent a year earlier to just 5 to 10 percent. Cardiac catheterization pinpointed the likely culprit: in-stent restenosis, a re-narrowing inside the previously placed coronary stent.

Interventional cardiologists opened the blocked stent with angioplasty and deployed a second drug-eluting stent, loading the patient with aspirin and clopidogrel, two antiplatelet drugs that further raise bleeding risk. Despite the revascularization, his requirement for inotropic drugs, medications that force the weakened heart to contract harder, kept climbing over the next 24 hours. The team planned an urgent TAVR-in-TAVR, meaning a new valve delivered by catheter inside the failing one, to relieve the persistent shock. Before that could happen, the patient deteriorated into pulseless electrical activity, a rhythm in which the heart’s electrical system fires but no mechanical pumping follows. Advanced cardiovascular life support protocols were initiated, and the ECMO team was mobilized for extracorporeal cardiopulmonary resuscitation, in which a machine takes over circulation while the underlying cause is treated.

The cannulation itself was engineered to waste as little blood as possible. Over a no-flow period of just one minute followed by a low-flow period of 44 minutes, for a total of 45 minutes of CPR, the team percutaneously inserted a 25 French drainage cannula into the right common femoral vein and a 17 French return cannula into the left common femoral artery. Manual pressure was applied continuously whenever dilators were exchanged, a simple but critical maneuver to prevent ooze from the access site. A 6 French distal perfusion cannula, placed with a micropuncture needle, protected the leg from ischemia. Before anything else proceeded, the team confirmed with the family exactly which interventions the patient’s faith permitted: cardiopulmonary bypass, ECMO, and cell saver technology, which recovers and returns the patient’s own blood, were all acceptable, while allogeneic transfusions were not.

With mechanical support running, the bloodless medicine protocol swung into action. The patient received daily infusions of epoetin alfa, a synthetic version of the hormone that drives red blood cell production in the bone marrow, at 20,000 units per day with a boost of 40,000 units on the day of cannulation and valve replacement. Intravenous ferric gluconate supplied the iron raw material for hemoglobin synthesis, while daily cobalamin and folic acid supported the cellular machinery of hematopoiesis. Blood draws, a notorious cause of hospital-acquired anemia in the critically ill, were minimized, clustered together, and performed with pediatric collection tubes that require only tiny volumes. Nutrition was carefully maintained, because malnutrition worsens both anemia and coagulopathy. All of this had to coexist with therapeutic heparin anticoagulation and dual antiplatelet therapy, a pharmacological tightrope walk between clotting in the circuit and bleeding from every puncture site.

Three days after ECMO cannulation, the patient underwent the transfemoral TAVR-in-TAVR procedure. Every vascular access was obtained under combined ultrasound and fluoroscopic guidance using micropuncture needles in a single pass, a technique that maximizes the chance of first-stick success and minimizes hematoma formation. Ten days after cannulation, the team successfully weaned him from V-A ECMO and decannulated him, returning the blood remaining in the circuit to his body and repairing both cannulation sites primarily. The numbers tell the story of how close the margins were. His hemoglobin stood at 11.7 grams per deciliter on the day of cannulation, fell to 7.5 by decannulation, and touched a nadir of 6.3 during the admission. Platelets dropped from 180,000 per cubic millimeter at ECMO initiation to 92,000 at decannulation, with a low of 73,000 on the circuit. He remained therapeutically anticoagulated throughout the entire support period.

The outcome, measured over a full year, was remarkable. At discharge, his ejection fraction had recovered to 15 to 20 percent and the valve gradient had fallen from 43 to 12.7 mmHg. At one year, the ejection fraction reached 30 to 35 percent with a gradient of 9 mmHg and only trace aortic insufficiency. Neurologically, he was intact, oriented to person, place, time, and situation, with no deficits despite 45 minutes of resuscitation. He spent 46 days in the hospital and was discharged to a long-term acute care facility, initially requiring maximum assistance with daily activities alongside occupational and physical therapy. The only ECMO-related complication was a polymicrobial infection at the surgical cutdown site, involving E. coli, S. marcescens, and E. faecium, which required antibiotics, surgical re-exploration, and a vacuum-assisted closure device. Notably, he received no transfusions at any point despite multiple cardiovascular interventions.

The case matters because the statistics for bleeding during extracorporeal resuscitation are sobering. Depending on how bleeding is defined, between 9 and 40 percent of ECPR patients experience hemorrhage requiring transfusion, and the SAVE-J II trial demonstrated that as many as 64 percent of ECPR patients need blood, sometimes up to ten units of packed red cells on top of fresh frozen plasma and platelets. Known risk factors include thrombocytopenia at presentation, older age, elevated D-dimer, surgical or central cannulation, and renal replacement therapy, and this patient carried several of them. Jehovah’s Witnesses, whose faith prohibits blood product transfusion, have therefore often been considered poor candidates for ECMO, and published reports of successful bloodless ECPR remain scarce. The Temple team argues that being a Witness is not an absolute contraindication, provided an algorithmic approach is followed and decisions are made jointly with the patient and family.

The protocol they describe extends well beyond this single case. Ultrasound-guided vascular puncture avoids repeated needle sticks that cause hematomas and limb ischemia, and a two-person cannulation team allows continuous manual pressure during equipment exchanges. Retrograde autologous priming, in which the patient’s own blood displaces the crystalloid fluid that fills the circuit, can prevent hemodilution when time permits. Once on support, the authors suggest considering anticoagulation targets below the standard ELSO recommendation of an aPTT 1.5 to 2.5 times baseline or an anti-Xa level of 0.3 to 0.7 IU/mL, balancing thrombotic risk against bleeding, guided by institutional protocols. Should hemorrhage occur, they recommend a predetermined multidisciplinary plan: stop systemic anticoagulation immediately, administer acceptable hemostatic alternatives, and intervene early for mechanical control. Shortening the duration of support matters too, since rapid liberation from V-A ECMO is independently associated with fewer bleeding complications, and weaning should proceed only once hemodynamics are unequivocal to avoid re-cannulation.

What elevates this report from a curious anecdote to a reference point is its demonstration that bloodless medicine, usually planned weeks in advance for elective surgery, can be executed in the chaos of an emergency resuscitation. The key elements, careful cannulation technique, hematopoietic support, minimized phlebotomy, nutritional optimization, and meticulous circuit management, are all deployable once a patient is stabilized on the machine. With well-defined goals of care agreed upon in advance and a disciplined, algorithmic approach, the authors conclude that extracorporeal cardiopulmonary resuscitation can be a viable option for Jehovah’s Witness patients in cardiac arrest. Given how few such cases have been reported with successful outcomes, this experience offers clinicians a practical roadmap for one of the most challenging scenarios in critical care, and a reminder that respecting a patient’s religious convictions and delivering aggressive, life-saving technology need not be mutually exclusive.

Subject of Research: Bloodless extracorporeal cardiopulmonary resuscitation with ECMO in a Jehovah's Witness patient

Article Title: Extracorporeal cardiopulmonary resuscitation for cardiogenic shock in a Jehovah’s witness

Article References: Afflu, D. K., F. Chai, L., Kehara, H., Baskin, S. M., Toyoda, Y., & Yanagida, R. (2026). Extracorporeal cardiopulmonary resuscitation for cardiogenic shock in a Jehovah’s witness. Journal of Artificial Organs, 29(4), Article 65. https://doi.org/10.1007/s10047-026-01591-6

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01591-6

Keywords: ECMO, ECPR, cardiogenic shock, Jehovah's Witness, bloodless medicine, mechanical circulatory support, TAVR, cardiac arrest, blood conservation, anticoagulation, epoetin, cardiac surgery

The Impella family of devices works by drawing blood from the left ventricle through an inlet area near the pump’s tip and expelling it into the ascending aorta, providing up to several liters per minute of forward flow while simultaneously unloading the failing ventricle. The pump motor and bearing assembly sit within the blood stream, and heat and mechanical stress make that region a nidus for thrombus formation. To prevent clot from accumulating around the motor, the device continuously flushes a sterile purge solution through the narrow clearance space between the rotor and the housing; the solution then exits into the circulation. Because this purge fluid is delivered directly into the patient’s blood, whatever is dissolved in it becomes part of the patient’s systemic drug exposure. Historically, the manufacturer’s instructions have called for heparin to be added to the purge solution, so the purge line acts as a continuous low-dose heparin infusion on top of whatever systemic anticoagulation the patient is already receiving.

That arrangement is straightforward when Impella is used alone, but it becomes genuinely complicated when ECMO is added. Patients on ECPELLA support are typically managed with systemic anticoagulation to protect the oxygenator and tubing of the extracorporeal circuit, guided by protocols such as those issued by the Extracorporeal Life Support Organization, whose 2021 adult and pediatric anticoagulation guidelines consolidated contemporary practice. Layering a heparin-containing purge on top of systemic heparin, or on top of an alternative agent such as bivalirudin, creates a second, parallel route of anticoagulant delivery whose contribution to the total dose is not independently measured by standard monitoring. Clinicians therefore face a balancing act: enough anticoagulation to protect two devices and a circuit, but not so much that bleeding, the most common complication of mechanical circulatory support, becomes life-threatening. Some centers have responded by removing heparin from the purge bag entirely, running the purge with anticoagulant-free solutions such as 5% dextrose in water or sodium bicarbonate, and relying on systemic anticoagulation to protect the pump.

The question is whether an anticoagulant-free purge actually protects the device. The purge flow rate is titrated to maintain a specified pressure gradient across the purge circuit, which serves as a proxy for patency of the tiny channels that bathe the motor; if those channels clot, purge pressure rises, the purge rate climbs to compensate, and in the worst case the pump malfunctions. Prior single-center experiences, including analyses of heparin 25 units per milliliter purge solutions and separate evaluations of bicarbonate-based purge solutions in patients with cardiogenic shock supported by Impella, have suggested that non-standard purge strategies can be workable, but the data remain limited and the patients most likely to receive ECPELLA, those in profound cardiogenic shock, have been underrepresented. The new study by Nathaniel J. Martin, Christoph G. S. Nabzdyk, Scott D. Nei, Andrew N. Rosenbaum, Troy G. Seelhammer, and Patrick M. Wieruszewski was designed to examine exactly this gap: Impella device function in patients receiving combined ECMO and Impella support, stratified by whether their purge solution contained heparin or not.

The design was observational and modest in scale, and the authors are explicit about its limits. The team identified 25 patients supported with ECPELLA at their institution. Fourteen of these patients received an anticoagulant-free purge solution, either 5% dextrose or sodium bicarbonate, while the remaining 11 received a heparin-containing purge solution. The median duration of ECPELLA support was five days, a duration long enough for purge-related thrombosis to become clinically apparent if it were going to occur. The primary observation of interest was Impella device malfunction attributable to purge failure, the outcome that would most directly signal that an anticoagulant-free purge was inadequate to keep the motor housing clear. Ethical approval for the study came from the Mayo Clinic Institutional Review Board, with a waiver of informed consent, consistent with the retrospective review of clinical care.

The headline finding is stark in its simplicity. Across the entire cohort, the only episode of Impella device malfunction occurred in a patient in the heparin-containing group. No patient in the anticoagulant-free group experienced a purge-related device failure during their course of support, and device longevity appeared acceptable in both groups. Read at face value, the result suggests that dextrose- or bicarbonate-based purge solutions, paired with systemic anticoagulation, did not compromise the mechanical integrity of the Impella during a median of five days of combined support. In an environment where every additional unit of heparin delivered through the purge line potentially shifts a critically ill patient’s hemostatic balance, a strategy that removes that infusion without evident device harm is clinically meaningful, even if the evidence behind it is still thin.

The authors themselves are careful not to overstate the case, and their caution is warranted for reasons that go to the heart of how small clinical studies work. With only 25 patients and a low overall event rate, the study cannot exclude a modest increase in device malfunction risk associated with anticoagulant-free purge solutions; the single malfunction in the heparin group, far from indicting heparin, illustrates precisely how noisy such comparisons are at this scale. Bleeding outcomes, thromboembolic events, and hemolysis, all of which matter enormously in this population, are not the focus of the abstract-level reporting, and confounding by indication is a live concern: the choice of purge solution likely reflected evolving institutional practice and individual patient characteristics rather than random assignment. The conclusion the authors draw is correspondingly measured. Given the low event rate and the apparent maintenance of acceptable device longevity, they write, use of anticoagulant-free purge solutions alongside systemic anticoagulation in ECPELLA patients may be reasonable, but the strategy requires validation in an appropriately powered study.

Even so, the study contributes to a broader and increasingly visible conversation about how anticoagulation should be managed across the growing arsenal of temporary circulatory support devices. Pharmacotherapy reviews have called for optimization of anticoagulation in Impella-supported patients, noting the tension between manufacturer recommendations, center-specific protocols, and the absence of definitive trial evidence. Comparisons of bivalirudin versus heparin for systemic anticoagulation during ECMO, published in Critical Care Medicine by members of the same Mayo group, reflect the same underlying effort to rationalize hemostatic management in extracorporeal support. The purge solution sits at an unusual intersection within this landscape: it is simultaneously a device-maintenance fluid and a systemic drug delivery route, and it is frequently overlooked in discussions that focus on the more visible systemic anticoagulants. Recognizing the purge line as a pharmacologic exposure, and studying it as one, is a conceptual step forward for the field.

For the bedside intensivist, pharmacist, and perfusionist managing an ECPELLA patient tonight, the practical takeaway is not a new protocol but a new data point in an evolving conversation. Anticoagulant-free purge solutions, whether 5% dextrose or sodium bicarbonate, have now been used in a consecutive series of ECPELLA patients at a high-volume center without evident compromise of device function over a median of five days of support. That observation will not end the debate, and no one should abandon heparinized purge on the strength of 25 patients, but it legitimizes the strategy as a subject for the large, prospectively designed comparative study it deserves. Until such a study exists, the choice of purge solution will remain a matter of institutional protocol and clinical judgment, exercised within the same delicate balance that defines all of extracorporeal support: keeping the blood fluid enough to survive the machine, and the patient solid enough to survive the bleeding. This small study suggests the balance can be struck without heparin in the purge bag, and that alone makes it worth the field’s attention.

Subject of Research: Impella purge solution strategy and device function in patients receiving combined ECMO and Impella (ECPELLA) support

Article Title: Impella purge solutions in patients receiving extracorporeal membrane oxygenation

Article References: Martin, N. J., Nabzdyk, C. G. S., Nei, S. D., Rosenbaum, A. N., Seelhammer, T. G., & Wieruszewski, P. M. (2026). Impella purge solutions in patients receiving extracorporeal membrane oxygenation. Journal of Artificial Organs, 29(4), Article 64. https://doi.org/10.1007/s10047-026-01595-2

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01595-2

Keywords: Impella, ECMO, ECPELLA, purge solution, anticoagulation, heparin, mechanical circulatory support, cardiogenic shock, left ventricular unloading, device malfunction, critical care, ventricular assist device

The clinical picture on presentation was dire. Acute severe mitral regurgitation had produced extreme respiratory failure despite maximal ventilatory support: while breathing pure oxygen, the patient’s arterial blood showed a pH of 7.144, a partial pressure of oxygen of only 48 mmHg, and a partial pressure of carbon dioxide of 101 mmHg. Those numbers describe profound, life-threatening hypoxemia and hypercapnia, the biochemical signature of lungs so waterlogged and failing that gas exchange had nearly collapsed. Fulminant pulmonary edema of this kind, driven by the sudden backflow of blood through an incompetent mitral valve, typically leaves clinicians with a narrow and dangerous window in which to act.

The standard emergency answer for such patients is often veno-arterial ECMO, in which blood is drained from the venous system, oxygenated outside the body, and returned to the arterial circulation, simultaneously supporting the heart and lungs. But the authors highlight a well-recognized paradox: VA-ECMO can worsen pulmonary congestion in patients with a failing left ventricle. By returning oxygenated blood to the aorta, it increases the afterload against which the damaged left ventricle must pump, which can push blood backward into the lungs and aggravate the very edema the therapy is meant to buy time against. Recent literature, including a 2024 position paper on dual-circulation physiology during venoarterial ECMO and multicenter data linking left ventricular unloading to lower mortality in cardiogenic shock, has sharpened attention on this problem and on strategies to relieve the loaded ventricle.

The surgical team proceeded with emergency mitral valve replacement under cardiopulmonary bypass. When the operation ended, however, the heart could not be weaned from the bypass machine: severe pulmonary edema and post-cardiotomy shock conspired to keep the ventricle too weak and the lungs too compromised for independent circulation. Rather than defaulting to VA-ECMO, the surgeons made a deliberate split decision. They implanted an Impella 5.5, an axial-flow catheter-mounted pump, directly into the ascending aorta through a prosthetic graft, positioning it across the aortic valve so it could draw blood out of the left ventricle and deliver it antegrade into the systemic circulation. Then they added veno-venous ECMO, which drains deoxygenated blood from the venous side and returns it oxygenated to the veins, supporting only the lungs.

The physiological logic of this combination is what makes the case compelling. The Impella 5.5 provides left ventricular unloading and forward systemic flow, reducing the pressure that would otherwise be transmitted back into the pulmonary vasculature, while VV-ECMO takes over gas exchange without adding any arterial afterload at all. In effect, the circulation and the respiration were decoupled and managed independently, avoiding the differential hypoxemia problem known as harlequin syndrome, in which poorly oxygenated blood ejected by the native heart mixes with oxygenated ECMO return in patients on VA-ECMO. The authors argue that this decoupled strategy may be an effective option for selected patients suffering concomitant severe respiratory and circulatory failure, particularly when VA-ECMO risks compounding pulmonary congestion.

The early postoperative course was rocky but revealing. The patient initially required substantial vasoactive and inotropic drug support to maintain blood pressure, a reflection of both the stunned post-cardiotomy myocardium and the inflammatory burden of prolonged critical illness. Serum lactate, a biochemical marker of inadequate tissue perfusion, peaked transiently at 10.9 mmol/L on postoperative day one, a level indicating significant anaerobic metabolism. Crucially, however, systemic perfusion was maintained throughout, and as the ventricle recovered, the team was able to stabilize the circulation on Impella-mediated antegrade flow alone, without ever converting to VA-ECMO or the hybrid V-AV configuration that many centers would have reached for in a similar situation.

Respiratory recovery followed a parallel and equally instructive trajectory. Under VV-ECMO-supported lung rest, with the membrane lung shouldering the work of oxygenation and carbon dioxide removal, and under an intensive diuretic regimen to strip away the excess lung water, the patient’s respiratory function improved progressively. Bilateral pulmonary opacities on imaging, the radiographic shadow of the edema, gradually cleared. VV-ECMO was removed on postoperative day three, a remarkably short run that suggests the lung injury, while fulminant, was largely hydrostatic and reversible once the circulatory derangement was corrected. The Impella 5.5 was explanted on postoperative day six as ventricular function recovered.

The outcome was a full survival: the patient was discharged on postoperative day 46 without any neurological sequelae, an outcome that would have been considered improbable at the moment of presentation, when his blood gases were incompatible with sustained life on conventional support. For a case report, the message is less about a single heroic save than about a reproducible physiological principle. The authors position the combination as a way to sidestep the afterload penalty of VA-ECMO while still providing both pump function and gas exchange, drawing on established techniques for direct aortic Impella implantation that allow the device to be placed surgically with secure fixation.

The report also underscores how rapidly the mechanical support landscape is evolving. The Impella 5.5, originally developed as a percutaneous left ventricular assist device for high-risk procedures and cardiogenic shock, is increasingly being combined with ECMO in creative configurations, and the literature now includes dedicated analyses of left ventricular decompression during VA-ECMO and reviews of the collision between native and device circulations. This case adds a new entry to that growing repertoire: instead of adding an Impella to unload a ventricle already supported by VA-ECMO, the team used the pump as the sole circulatory engine and paired it with purely respiratory extracorporeal support. The authors are careful to frame the approach as appropriate for selected patients, and a single case cannot establish superiority over conventional strategies. But for clinicians confronting the double failure of heart and lungs, particularly when pulmonary edema makes VA-ECMO counterproductive, the case provides a concrete, technically documented template. It suggests that thinking about circulatory and respiratory failure as separable problems, rather than as a single indication for one device, can turn a nearly certain death into a discharge home with an intact brain.

Subject of Research: Combined veno-venous ECMO and direct aortic Impella 5.5 support for emergency mitral valve replacement in acute severe mitral regurgitation with fulminant pulmonary edema

Article Title: Combined veno-venous ECMO and direct aortic impella 5.5 support enabling emergency mitral valve replacement in acute severe mitral regurgitation with fulminant pulmonary edema

Article References: Combined veno-venous ECMO and direct aortic impella 5.5 support enabling emergency mitral valve replacement in acute severe mitral regurgitation with fulminant pulmonary edema. (n.d.). https://doi.org/10.1007/s10047-026-01592-5

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01592-5

Keywords: veno-venous ECMO, Impella 5.5, mechanical circulatory support, left ventricular unloading, differential hypoxemia, mitral regurgitation, pulmonary edema, cardiogenic shock, mitral valve replacement, cardiac surgery, Journal of Artificial Organs, case report

The clinical story began long before the emergency that defined it. The boy was born at full term with a normal birth weight of 2608 grams, but by two months of age he was hospitalized for poor weight gain and declining cardiac function. Oral medications stabilized him enough for discharge after a two-month stay. Genetic testing eventually revealed a nonsense mutation, designated c.153C > G, in the TAZ gene, the molecular signature of Barth syndrome. This X-linked recessive condition arises from defects in an enzyme that remodels cardiolipin, a phospholipid essential to the structure and function of mitochondria, the energy-producing structures inside cells. The result is a constellation of problems: dilated cardiomyopathy in which the heart muscle stretches and weakens, generalized muscular hypotonia, and cyclical neutropenia that leaves patients vulnerable to infection. When the child was readmitted at one year of age with severe cardiac dysfunction and a brain natriuretic peptide level of 2096 pg/mL, a marker of profound heart strain, inotropic drugs failed to rescue him and he was transferred to Osaka for transplant registration and placement of a Berlin Heart EXCOR, the only durable ventricular assist device approved for small children in Japan.

His condition deteriorated faster than the transplant system could move. On admission he weighed just 6.1 kilograms and measured 67.5 centimeters. Echocardiography showed a left ventricle dilated to 38 millimeters, a z-score of +5.7 relative to normal body size, an ejection fraction of only 15 percent, and severe mitral regurgitation; his BNP had surged to 7667 pg/mL. Soon after arrival he developed runs of non-sustained ventricular tachycardia, a dangerous rhythm disturbance, and amiodarone therapy dropped his blood pressure. The team established venoarterial extracorporeal membrane oxygenation through neck vessels as an emergency salvage measure, but acute pulmonary congestion followed, forcing the decision to implant a biventricular assist device using centrifugal pumps. For the left side, surgeons used a 6-mm apical inflow cannula and a 6-mm arterial outflow cannula; for the right side, they placed a 14-Fr inflow cannula into the inferior vena cava via the right atrium and an 8-Fr outflow cannula into the distal pulmonary artery trunk, all secured with purse-string sutures.

What happened next is the technical heart of the report. The right ventricular assist device pumped roughly 900 mL/min, yet the left-sided pump could not function efficiently. The culprits were severe pulmonary hypertension and pulmonary regurgitation, which together prevented blood pushed into the pulmonary circulation from returning effectively to the left heart. In a decisive maneuver, the surgeons relocated the right-sided outflow cannula from the pulmonary artery into the left atrium, temporarily routing oxygenated blood directly to the left side of the heart and bypassing the obstructed pulmonary circuit. Left ventricular assist device flow stabilized at approximately 600 mL/min. The strategy bought time, but it carried trade-offs: left atrial cannulation raises the risk of systemic thromboembolism, and the circuit could not be disconnected from the artificial lung that oxygenates blood outside the body. The team therefore treated the configuration as a bridge within a bridge, to be dismantled as soon as the pulmonary vasculature could tolerate normal routing.

That evaluation came quickly. Cardiac catheterization on postoperative day 5, performed during temporary interruption of right-sided pumping, recorded a pulmonary artery pressure of 21/15 mmHg with a mean of 18 mmHg and a pulmonary vascular resistance index of 3.5 Wood units times meters squared, values indicating acceptable pulmonary vascular physiology. On postoperative day 13 the outflow cannula was moved back to the pulmonary artery trunk and the artificial lung was removed from the circuit. Bedside echocardiography then showed improving right ventricular contraction, but chest X-rays revealed progressing pulmonary congestion, which the surgeons attributed to excessive pulmonary blood flow generated by full right-sided support. Their response was a careful titration: right pump flow was gradually reduced to low-flow assistance. Throughout this period the left pump maintained a stable 900 mL/min flow and central venous pressure held near 12 mmHg even when right-sided support fell to 400 mL/min or was interrupted entirely, evidence that the native right ventricle and pulmonary circulation had recovered enough to fill the left pump on their own. Concerned about circuit thrombosis during prolonged low flow, the team removed the right ventricular assist device on postoperative day 20.

The recovery of other organs lagged behind the heart but eventually followed. Acute kidney and liver failure complicated the early postoperative course, requiring continuous hemodiafiltration from postoperative day 7. Bilirubin climbed as high as 15.1 mg/dL and renal dysfunction persisted for more than a month, but hemofiltration was discontinued on day 44, total bilirubin normalized on day 61, and the child was extubated on day 55. Only after these markers of end-organ recovery did the team secure in-house approval for heart transplant registration, the prerequisite under Japanese rules for implanting the Berlin Heart EXCOR, which was converted from the temporary centrifugal left ventricular assist device 76 days after the original biventricular implantation. The boy then remained stable on the pulsatile device for 374 days before undergoing successful heart transplantation, a total mechanical support journey of roughly 450 days from the first emergency pump to the donor heart.

The Osaka team frames the case within a strategy known as bridge to candidacy, an approach better documented in adults. In Japan, pediatric candidates face an average wait of 686 days for a donor heart, even though ten-year survival after pediatric transplantation reaches 96.2 percent, and by 2022 only 68 patients under 18 had ever been transplanted in the country. The Berlin Heart EXCOR has been approved there only since 2015 and only for patients already registered for transplantation, which creates a chicken-and-egg problem for infants whose comorbidities disqualify them from listing. Adult data show the workaround can succeed: large series report that short-term mechanical support can reverse refractory cardiogenic shock long enough for conversion to durable devices, with survival comparable to direct bridge-to-transplant pathways, though right ventricular support during the conversion emerges as a mortality risk factor. Pediatric evidence is thinner, but a Berlin group’s ten-year experience with 56 children and a multicenter United States study both suggest that prior extracorporeal support does not necessarily doom Berlin Heart outcomes, while low body weight, kidney and liver dysfunction, and biventricular support do worsen survival.

The case also contributes to a re-evaluation of Barth syndrome itself as a transplant indication. Because the condition combines heart failure with skeletal myopathy and immune compromise, patients were once considered unsuitable candidates, but after the first successful transplant in 1997, London investigators reported four successful cases, and a registry analysis of 43 transplanted Barth patients found outcomes for survival, infection, malignancy, and graft vasculopathy essentially equivalent to those of other recipients. The Osaka authors add an important caveat drawn from recent metabolic studies: transplantation does not fully normalize exercise tolerance, muscle mass, or substrate metabolism, because the underlying cardiolipin defect persists in skeletal muscle and other tissues. Their patient was not systematically assessed for these parameters after transplantation, a limitation the team acknowledges, and long-term multidisciplinary follow-up of neurodevelopment and metabolic status continues.

Beyond the individual rescue, the report is a detailed argument for staged, physiology-driven management of the failing right heart in small children. When pulmonary hypertension and valve regurgitation sabotage the left-sided pump, temporarily diverting right-sided outflow to the left atrium can stabilize the circulation; once catheterization confirms that pulmonary vascular resistance has fallen, rerouting to the pulmonary artery removes the thrombotic risk of left atrial cannulation and permits artificial lung removal, and stepwise flow reduction then tests whether the native right ventricle can carry the load. In this case that sequence converted a child in refractory cardiogenic shock with failing kidneys and liver into a registered transplant candidate with a durable device. The authors suggest the approach may extend the bridge-to-candidacy strategy to other high-risk pediatric patients with biventricular failure complicated by pulmonary hypertension, a population for whom waiting lists are long and options have historically been few.

Subject of Research: Bridge-to-candidacy mechanical circulatory support and heart transplantation in a pediatric patient with Barth syndrome-associated biventricular heart failure

Article Title: Successful bridge to heart transplantation in a pediatric patient with biventricular heart failure associated with Barth syndrome: a case report

Article References: Arita, K., Kido, T., Taira, M., Watanabe, T., Narita, J., Ishida, H., Ishii, R., Ueno, T., & Miyagawa, S. (2026). Successful bridge to heart transplantation in a pediatric patient with biventricular heart failure associated with Barth syndrome: a case report. Journal of Artificial Organs, 29(4), Article 60. https://doi.org/10.1007/s10047-026-01587-2

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01587-2

Keywords: Barth syndrome, heart transplantation, ventricular assist device, Berlin Heart EXCOR, biventricular heart failure, pediatric cardiology, pulmonary hypertension, cardiogenic shock, mechanical circulatory support, TAZ gene, dilated cardiomyopathy, bridge to candidacy

The report centers on a man in his fifties who developed pump thrombosis just fourteen days after receiving a HeartMate 3 implant. The HeartMate 3, manufactured by Abbott, is a fully magnetically levitated centrifugal-flow pump designed to minimize blood trauma. Its artificial pulse feature and wide blood-flow gaps were engineered specifically to reduce the risk of thrombosis, and large randomized trials have indeed shown remarkably low rates of pump thrombosis compared with older axial-flow devices. That very success, however, means that when thrombosis does occur, clinicians may have little experience recognizing it, particularly in the early postoperative period when it is rarest and hardest to diagnose.

In this case, the patient’s initial presentation was strikingly subtle. He remained clinically stable, with no overt signs of heart failure, device malfunction, or systemic illness. Laboratory abnormalities were present but mild, lacking the dramatic elevations in plasma free hemoglobin and lactate dehydrogenase that classically accompany pump thrombosis and that form the backbone of established diagnostic algorithms. What stood out instead was the device’s own telemetry: an abrupt decline in estimated pump flow recorded by the system monitor. In a device that continuously reports flow, power, pulsatility index, and speed, a sudden fall in flow is a mechanical statement that something is obstructing the blood’s path through the pump or its conduits.

The clinical team pursued the signal aggressively. Contrast-enhanced computed tomography was performed, and the imaging raised suspicion of thrombus formation within the outflow graft, the conduit that carries blood from the pump into the aorta. Faced with a plausible mechanical obstruction and a device already showing declining performance, the surgeons proceeded to an emergent pump exchange. The decision proved prescient. Subsequent analysis of the explanted device by the manufacturer demonstrated thrombus attached to the metallic edge at the inflow aspect of the pump, the region where blood enters from the left ventricle. Notably, no thrombus was identified on the rotor or on the impeller blade surfaces, indicating that the clot had lodged at the pump’s entry rather than accumulating on its moving parts.

This anatomical detail matters because it helps explain the paradoxical laboratory picture. Hemolysis, the destruction of red blood cells that releases free hemoglobin into plasma, is most severe when thrombus interacts directly with the rapidly spinning rotor. A thrombus sitting at the inflow edge, partially obstructing inflow rather than churning against the impeller, can reduce flow while generating comparatively little shear-related blood damage. The result is a thrombotic event that evades the standard biochemical radar. The authors argue that this case exposes the limitations of relying solely on laboratory findings for early detection and prediction of early HeartMate 3 pump thrombosis, and they emphasize that an abrupt decline in pump flow, even in the absence of marked hemolysis or increased pump power, may represent an early and clinically important warning indicator.

The diagnostic challenge in continuous-flow ventricular assist devices is well documented in the literature the authors cite. Algorithms developed more than a decade ago, including the widely used approach published by Goldstein and colleagues in 2013, built diagnosis around a constellation of findings: hemolysis, rising pump power, low flow, and echocardiographic abnormalities. Later work by Scandroglio and colleagues refined the evaluation of blood flow obstructions, and a systematic analysis by Kaufmann and colleagues in 2022 catalogued thrombus formation at the inflow cannula of continuous-flow devices. Yet the HeartMate 3’s hemocompatibility profile has shifted the epidemiology. Pump thrombosis is now so uncommon that individual cases carry outsized educational value, and each one refines the community’s understanding of how the complication can present.

Early postoperative thrombosis is a particularly treacherous subset. Reported cases include thrombosis within one hour of implantation, intraoperative pump thrombosis, and acute events in the first days after surgery, as documented by Shah and colleagues, Karuppiah and colleagues, and Bunge and colleagues in separate reports. The early period is a perfect storm of prothrombotic conditions: fresh surgical surfaces, inflammatory activation, altered anticoagulation management, and a healing heart adapting to unloading by the new device. A patient in this window who develops a flow abnormality may be dismissed as having volume shifts, arrhythmia, or right heart dysfunction, all of which can alter pump flow estimates. The Kurume case demonstrates why an abrupt change should instead prompt immediate structural evaluation rather than watchful waiting.

The technology itself deserves attention in understanding why flow telemetry is such a sensitive indicator. The HeartMate 3 operates at a fixed speed set by the clinician, typically around 5,000 to 6,000 revolutions per minute, and the controller estimates flow from the relationship between power consumption and speed. When inflow becomes obstructed, the pump essentially runs against a partial vacuum, and the estimated flow falls even though the impeller continues spinning at its commanded speed. Pump power, by contrast, may change little when the obstruction is at the inflow rather than within the rotor region, which is precisely the pattern observed here. The artificial pulse, a periodic speed modulation unique to the HeartMate 3 that washes all surfaces of the pump, also influences the flow waveform, and clinicians familiar with its normal pulsatility signature can detect deviations that suggest inflow problems. In this case, the flow decline was abrupt enough to stand out against the patient’s baseline, functioning as the device’s own distress signal.

Contrast-enhanced computed tomography emerged as the decisive diagnostic step, and its role in this case reinforces a growing consensus that imaging should be part of the early evaluation of suspected device obstruction. Echocardiography remains the first-line tool for assessing inflow cannula position, ventricular size, and valve function, but it can miss thrombus within the outflow graft or at the pump’s inflow edge. Computed tomography with contrast offers a direct view of the entire blood path from ventricle to aorta, and in this patient it converted an ambiguous telemetry finding into a surgical indication. The authors’ sequence, from flow alarm to laboratory review to cross-sectional imaging to emergent exchange, effectively models the pathway they believe should be followed when abrupt flow decline appears without an obvious hemodynamic explanation.

The broader message for the mechanical circulatory support community is one of vigilance and humility about traditional markers. The HeartMate 3 has transformed outcomes for patients with advanced heart failure, with five-year results from the MOMENTUM 3 trial showing superior survival and fewer adverse events than earlier devices. But hemocompatibility is not immunity, and the rare thrombosis that does occur may present in atypical ways. The Kurume team, supported in part by a Japan Society for the Promotion of Science KAKENHI grant, closes their report with a clear clinical directive: prompt recognition and intervention are essential to prevent clinical deterioration. For the thousands of clinicians who monitor HeartMate 3 patients through daily device downloads, the case reframes a familiar number on the screen. An abrupt fall in pump flow is not a curiosity to be observed; it is a call to action, potentially the first and only warning that a life-sustaining pump is beginning to clot from the inside.

Subject of Research: Early detection of HeartMate 3 pump thrombosis using abrupt pump flow decline as an initial warning indicator

Article Title: Abrupt flow decline as the initial indicator of early HeartMate 3 pump thrombosis

Article References: Ishii, Y., Kato, T. S., Takagi, K., Sano, S., Yoshimatsu, S., Shinoda, M., Yanai, T., Shibata, T., Uehara, M., Uchimura, H., Sugihara, G., Fukumoto, Y., & Tayama, E. (2026). Abrupt flow decline as the initial indicator of early HeartMate 3 pump thrombosis. Journal of Artificial Organs, 29(4), Article 61. https://doi.org/10.1007/s10047-026-01588-1

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01588-1

Keywords: HeartMate 3, pump thrombosis, LVAD, mechanical circulatory support, pump flow, hemolysis, outflow graft, computed tomography, heart failure, ventricular assist device, low flow alarm, device thrombosis

The HeartMate 3, a fully magnetically levitated continuous-flow pump, has become a workhorse of advanced heart failure therapy worldwide, offering durable support both as a bridge to transplantation and as destination therapy. Because the pump maintains a constant flow through the circulatory system, its external controller continuously estimates flow and triggers alarms when values fall below a preset low flow limit, or LFL. That alarm serves as an early warning for potentially dangerous conditions such as pump thrombosis, inflow obstruction, hypovolemia, or arrhythmias. The factory-standard setting is 2.5 liters per minute, but clinicians have increasingly recognized that some patients—particularly those of smaller body habitus—may run baseline flows close enough to that threshold that nuisance alarms become a daily occurrence, eroding quality of life and prompting careful discussions about whether the alarm limit can safely be lowered.

In a retrospective observational study published in the Journal of Artificial Organs, a team led by Hiroshi Nishioka of the National Cerebral and Cardiovascular Center in Suita, Osaka, and Takuma Sato of the same institution’s Department of Transplant Medicine set out to determine which preoperative characteristics predicted the need for postoperative replacement of the standard controller with one configured to a low flow limit of 2.0 liters per minute. The researchers analyzed 127 patients who underwent primary HeartMate 3 implantation at their center between June 2019 and March 2025. Of these, 78 patients maintained the standard 2.5 liter-per-minute controller throughout follow-up, while 49 required replacement with a controller set to the lower 2.0 liter-per-minute threshold.

The comparison between the two groups revealed a striking pattern. Patients who ultimately needed the lower alarm limit were significantly smaller across every anthropometric measure examined: they were shorter, weighed less, had lower body mass index, and, most consequentially, had smaller body surface area. They also tended to have a shorter history of heart failure before implantation. By contrast, the study found no significant differences between the groups in a broad battery of clinical, echocardiographic, and hemodynamic variables, suggesting that the conventional parameters clinicians often scrutinize before implantation—measures of cardiac function and pumping performance—did not separate the two groups.

To move from association to prediction, the researchers applied multivariate logistic regression, a statistical technique that evaluates each candidate variable’s independent contribution while holding the others constant. When all the clinical, laboratory, echocardiographic, and hemodynamic measurements were weighed together, body surface area emerged as the sole independent predictor of postoperative controller replacement. The effect size was dramatic: each unit increase in body surface area was associated with an odds ratio of 0.03, meaning that larger patients were overwhelmingly less likely to require the lower alarm limit. The 95 percent confidence interval ranged from 0.00 to 0.60, and the result reached statistical significance with a p-value of 0.022.

The team then used receiver operating characteristic curve analysis to translate that statistical association into a clinically usable threshold. This method plots a test’s sensitivity against its specificity across all possible cutoff values, allowing researchers to identify the value that best discriminates between groups. A preoperative body surface area of 1.43 square meters proved to be the optimal cutoff, yielding an area under the curve of 0.74—indicating moderate discriminatory power—with a specificity of 89.7 percent and a sensitivity of 38.8 percent. In practical terms, a patient whose body surface area falls below 1.43 square meters is very likely to be among those who will need the lower alarm limit, while the relatively modest sensitivity means that some patients above the cutoff will still require it. The authors are transparent about this trade-off: the threshold is highly specific but only moderately sensitive, making it best suited for identifying patients who clearly warrant a 2.0 liter-per-minute controller from the outset.

The clinical logic behind lowering the alarm limit in smaller patients rests on the physiology of continuous-flow circulatory support. Pump flow scales with the metabolic demands of the body, and smaller patients simply generate lower absolute flows at any given support setting. When baseline flows hover near 2.5 liters per minute, the standard alarm threshold produces frequent false alarms during routine activity, dehydration, or minor hemodynamic shifts. Frequent alarms are not merely an annoyance; studies of left ventricular assist device patients have linked alarm burden to anxiety, sleep disruption, and reduced quality of life, and they can lead patients and caregivers to become desensitized to alerts, potentially delaying recognition of genuine emergencies. Lowering the limit to 2.0 liters per minute preserves the protective function of the alarm for truly dangerous low-flow states while eliminating the constant noise of alerts triggered by the patient’s normal operating range.

Until now, however, the decision to swap the standard controller for a 2.0 liter-per-minute version has typically been reactive: clinicians implant the device with factory settings, observe alarm behavior over weeks or months, and then arrange for controller replacement in those who struggle. Each replacement carries practical costs—additional hospital visits, device reprogramming, patient education, and the logistics of exchanging a life-sustaining external component. The study’s authors argue that a proactive approach, guided by the 1.43 square meter body surface area threshold, could spare many smaller patients an unnecessary second procedure while ensuring that the alarm system remains calibrated to their physiology from day one. Because the cutoff is derived from a measurement taken routinely at every preoperative evaluation, implementing it would require no additional testing, only a change in configuration practice.

The findings come amid rapid growth in mechanical circulatory support. The most recent annual report from the Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support documented expanding use of the HeartMate 3 across age groups, including growing experience in pediatric and small-statured patients through networks such as the Advanced Cardiac Therapies Improving Outcomes Network. As the device is implanted in increasingly diverse populations, individualizing device settings becomes more pressing. The Japanese cohort studied here reflects a national experience in which body size distributions differ from those in Western registries, and the authors caution that their results derive from a single center; validation in larger, multi-center and ethnically diverse cohorts will be needed before the 1.43 square meter threshold can be adopted as a universal standard.

Nevertheless, the elegance of the result lies in its simplicity. In an era when artificial hearts are guided by sophisticated algorithms and magnetically levitated rotors, one of the most useful predictors of device configuration turns out to be a number calculated from height and weight. For clinicians implanting the HeartMate 3, the message is concrete: check the body surface area before surgery, and for patients below roughly 1.43 square meters, consider reaching for the 2.0 liter-per-minute controller at the start. For the growing community of patients living with these pumps, it could mean fewer alarms, fewer controller exchanges, and a device experience better matched to the bodies it sustains.

Subject of Research: Preoperative prediction of low flow limit controller configuration after HeartMate 3 implantation

Article Title: Preoperative predictors of low flow limit controller configuration following HeartMate 3 implantation

Article References: Nishioka, H., Sato, T., Komiyama, M., Iwanaga, K., Tonai, K., Kitahata, N., Takahashi, Y., Miyagawa, S., Sawada, K., Yotsuida, H., Tadokoro, N., Fukushima, S., Fujita, T., Fujisato, T., & Tsukamoto, Y. (2026). Preoperative predictors of low flow limit controller configuration following HeartMate 3 implantation. Journal of Artificial Organs, 29(4), Article 62. https://doi.org/10.1007/s10047-026-01590-7

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01590-7

Keywords: HeartMate 3, left ventricular assist device, body surface area, low flow limit, low-flow alarm, controller configuration, advanced heart failure, mechanical circulatory support, quality of life, cardiac surgery, LVAD, predictive threshold

Magnetostatic pumping leverages the principles of magnetism to facilitate fluid movement within a system, which in this case, is essential for ensuring adequate blood flow and oxygenation in patients experiencing severe respiratory failure or circulatory shock. Traditional ECMO devices, while effective, are often marred by various limitations, including mechanical complexities and logistical challenges regarding implantation and maintenance. The innovative approach described in this study offers a simplified, yet efficient alternative that could improve operational efficiency in high-stakes environments.

In their experiments, Zolala and his colleagues utilized an ex vivo model to simulate clinical conditions that would necessitate ECMO intervention. This model allowed them to manipulate variables and observe the effects of magnetostatic pumping in real-time, providing valuable insights into its potential efficacy and safety. By employing advanced imaging technologies, the team was able to track fluid dynamics and assess the function of the pump under various conditions, revealing noteworthy outcomes that could lead to enhanced patient survival rates.

One of the most striking findings of this study is the ability of the magnetostatic pump to maintain consistent blood flow rates while minimizing hemolysis – the destruction of red blood cells – a common complication associated with conventional ECMO systems. This breakthrough could significantly reduce the adverse effects often seen in patients requiring such complex interventions, a finding that is paramount in critical care medicine where patient stability is essential for recovery.

From a technical standpoint, the researchers meticulously detailed the design and operation of the magnetostatic pump. The mechanism involves the careful positioning of magnets that create a magnetic field strong enough to propel fluid through tubing, emulating the natural pulsatile flow of the heart. This innovative approach circumvents several mechanical components typically found in traditional pumps, reducing the overall footprint and complexity of the device, thus enhancing portability and ease of use in both hospital and field settings.

The research team also conducted extensive testing to compare the magnetostatic pump’s performance against conventional pneumatic pumps utilized in current ECMO technology. The results were promising; not only did they achieve superior flow rates, but the tactile feedback from the magnetostatic mechanism provided a greater sense of control during clinical applications. This creates exciting possibilities for medical professionals who often grapple with the unpredictability of current ECMO devices under stressful circumstances.

Furthermore, the study highlighted the ease of integration of the magnetostatic system with existing ECMO setups, allowing for a seamless transition for healthcare providers. Such adaptability is crucial in emergency medical situations, where time and efficiency can be the difference between life and death. This enhancement in procedural fluency is expected to be a vital contributor to positive clinical outcomes in critical care scenarios involving ECMO.

Another significant aspect of the research is its potential impact on healthcare costs. Given that ECMO procedures can be prohibitively expensive due to the complexity of the machines and the skilled personnel required to operate them, the introduction of a more straightforward and cost-effective method like magnetostatic pumping could lead to broader accessibility. If these systems can be manufactured at lower costs while maintaining or improving efficacy levels, healthcare facilities may be more inclined to adopt this technology, ultimately benefiting more patients in need of life-saving treatments.

The promising findings from the research also lay the groundwork for future studies aimed at optimizing magnetostatic pumping for various clinical applications beyond ECMO. For instance, applications in other scenarios requiring fluid transport, such as dialysis or infusion treatments, could be explored, expanding the utility of this innovative technology. This illustrates the versatility of magnetostatic principles, which may have far-reaching implications in medical engineering and patient care.

There remains, however, a need for further research to delineate the long-term effects and potential challenges associated with implementing magnetostatic pumps in clinical practice. The study by Zolala et al. is a critical starting point that highlights the need for additional controlled trials to validate their findings in diverse patient cohorts. The transition from experimental to widely adopted clinical practices is seldom straightforward, often necessitating rigorous testing and validation phases to ensure patient safety and device efficacy.

In conclusion, Zolala et al.’s research on magnetostatic pumping represents a significant advancement in ECMO technology with the potential to reshape patient care in critical medicine. As the medical community approaches the challenges of complex respiratory and circulatory support, innovations like this offer hope for improved outcomes and more efficient healthcare delivery. The possibility of healthier, more resilient patients in our hospitals could become a reality as we continue to innovate and refine life-saving technologies.

As the dust settles from this important research, one cannot help but feel a sense of anticipation for the next steps. The potential societal impact cannot be stressed enough, as advancements of this nature spark discussions not only in surgical rooms but also in boardrooms of healthcare facilities contemplating cost efficiencies. As we look forward to more breakthroughs, one can only imagine the lives that will benefit from these pioneering efforts in medical technology.

Subject of Research: Magnetostatic pumping in an ex vivo extracorporeal membrane oxygenation model.

Article Title: Magnetostaltic pumping in an ex vivo extracorporeal membrane oxygenation model.

Article References:

Zolala, M., Heim, V., Denis, C.V. et al. Magnetostaltic pumping in an ex vivo extracorporeal membrane oxygenation model.
J Transl Med (2026). https://doi.org/10.1186/s12967-026-07734-w

Image Credits: AI Generated

DOI: 10.1186/s12967-026-07734-w

Keywords: Magnetostatic pumping, extracorporeal membrane oxygenation, critical care technology, blood flow dynamics, hemolysis reduction, cost-effectiveness in healthcare.